Evidence map›Paper›PMID 42697176›Full record

ReviewThe journal of prevention of Alzheimer's disease2026

Integrating frailty into decision-making for disease-modifying therapies in Alzheimer's disease: a proposed expert-opinion based approach.

Giuseppe Bellelli, Ovidio Brignoli, Marco Canevelli, Antonio Cherubini, Andrew Clegg, Bruno Dubois, Maria Cristina Ferrara, Laura Fratiglioni, Giovanni B Frisoni, Giulia Grande and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Giuseppe BellelliUniversity of Milano Bicocca and Acute Geriatric Unit, IRCCS San Gerardo dei Tintori, 20900 Monza, Italy. Electronic address: giuseppe.bellelli@unimib.it.
Ovidio BrignoliGeneral Practitioner, Italian College of General Practitioners, 50144 Firenze, Italy.
Marco CanevelliDepartment of Human Neuroscience, Sapienza University, Rome, Italy and Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 11330 Stockholm, Sweden.
Antonio CherubiniGeriatria, Accettazione geriatrica e Centro di ricerca per l'invecchiamento. IRCCS INRCA, 60127 Ancona, Italy; Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Andrew CleggAcademic Unit for Ageing and Stroke Research, Bradford Institute for Health Research Bradford Institute for Health Research, BD96RJ Bradford, UK.
Bruno DuboisInstitut de la Mémoire et de la Maladie d'Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, 75013 Paris, France; Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Hôpital de la Pitié-Salpêtrière, 75013 Paris, France.
Maria Cristina FerraraUniversity of Milano Bicocca and Acute Geriatric Unit, IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Laura FratiglioniAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 11330 Stockholm, Sweden.
Giovanni B FrisoniCentre de la mémoire, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, 1211 Geneva, Switzerland.
Giulia GrandeAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 11330 Stockholm, Sweden.
Frank JessenKlinik und Poliklinik für Psychiatrie und Psychotherapie, Uniklinik Köln, Medizinische Fakultät, Kerpener Straße 62, 50937, Köln, Deutschland, Germany.
Sean P KennellyInstitute of Memory and Cognition, Tallaght University, D24NR0A Dublin, Ireland; Dept of Medical Gerontology, School of Medicine, Trinity College Dublin, D02PN40 Dublin, Ireland.
Alberto MagniGeneral Practitioner, Italian College of General Practitioners, 50144 Firenze, Italy.
Martina MarelliUniversity of Milano Bicocca and Acute Geriatric Unit, IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Alessandra MarengoniAging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, 11330 Stockholm, Sweden; Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy.
Nicolás Martínez VelillaNavarre Health Service (SNS-O), Navarre University Hospital (HUN), Department of Geriatrics, Navarrabiomed, Navarre Public University (UPNA), Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain and CIBER of Frailty and Healthy Aging (CIBERFES), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Susan D ShenkinAgeing and Health, and Advanced Care Research Centre, Usher Institute, University of Edinburgh, EH164UX Edinburgh, Scotland, UK.
Marc Suárez-CalvetBarcelona Brain Health Center, Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005 Barcelona, Spain and Barcelona Brain Health Center, Department of Neurology, Hospital del Mar, 08003 Barcelona, Spain.
Suzanne TimmonsCentre for Gerontology and Rehabilitation, School of Medicine, University College Cork, T12XH60 Cork, Ireland.
Alessandro PadovaniDepartment of Clinical and Experimental Sciences, University of Brescia, and Neurobiorepository and Laboratory of Advanced Biological Markers, University of Brescia and ASST Spedali Civili Hospital, 25123 Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of disease-modifying therapies for Alzheimer's disease (AD-DMTs) is reshaping clinical practice, raising critical questions about patient selection, diagnostic pathways, treatment appropriateness, and equity of access. Frailty, a multidimensional condition of reduced physiological reserve and increased vulnerability to stressors, is common in older adults with AD, yet has not been systematically assessed in AD-DMTs trials, limiting the generalizability of trial findings to real-world populations. In this review, we examine the role of frailty in the emerging era of AD-DMTs, summarizing evidence on its prevalence and prognostic relevance, approaches to its assessment, and its potential impact on treatment safety and effectiveness. We propose that regular frailty assessment should inform decision-making in both clinical trials and clinical practice, while frailty-informed management-including medication review and multidomain interventions-may support more appropriate, individualized care.

Indexed as

Alzheimer’s diseaseDisease-modifying therapyFrailtyOlder adults

Identifiers

PMID42697176
PMCPMC13571997

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.